JPRN-UMIN000030030RecruitingPhase 2
TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial - TAS-CC4 Study
Department of Digestive Surgery,Nippon Medical School0 sites45 target enrollmentStarted: March 1, 2018Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 45
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 80years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)contraindications for TAS-102 and Bevacizumab 2)previously received chemotherapy with TAS-102 3)severe drug allergy 4)pregnant woman or Possibility of the pregnant woman. male patient who hoping partner's pregnancy. 5)patient who has important clinical complications(symptomatic unstable ischemic heart disease, arrhythmia, acute myocardial infarction within 6 months, liver cirrhosis, renal failure, active gastrointestinal ulcer, ileus, uncontrolled diabetes, uncontrolled hypertension, etc.) 6)other active malignancies 7)have pleural effusion and ascitic fluid with the treatment 8)Comorbidity or history of heart failure 9)gastrointestinal ulcer or bleeding 10)previous hemoptysis 11)Clinical or radiological evidence of CNS metastases 12)Current or previous (within the last 6 months) history of GI perforation 13)Patient with interstitial pneumonia or lung fibrosis confirmed in imaging study 14)ongoing treatment with anticoagulant 15)Synchronous or metachronous multiple malignancy within the last 5 year disease free interval 16)Under continuous steroid administration 17)decision of unsuitable for this study by the investigator
Investigators
Similar Trials
Not yet recruiting
Phase 2
TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trialmetastatic colorectal cancerJPRN-UMIN000022438Teikyo University Chiba Medical Center31
Not yet recruiting
Phase 2
TAS-102 and Bevacizumab as second line chemotherapy for colorectal cancer. Phase 2 trialmetastatic colorectal cancerJPRN-UMIN000022437Teikyo University Chiba Medical Center20
Completed
Phase 2
TAS-102 and Bevacizumab as salvage line chemotherapy for colorectal cancerColorectal CancerJPRN-UMIN000031790Surgical Oncology Association in Chiba (SOAC)45
Completed
Phase 2
TAS-CC4 Studycolorectal cancerJPRN-jRCTs031180424Yamada Takeshi45
Not yet recruiting
Phase 2
TAS-102 plus Bevacizumab combination as salvage therapy in elderly patients with metastatic colorectal cancer, phase 2 trialmetastatic colorectal cancerJPRN-UMIN000021664Tokushima University Hospital25
